728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

PMD Solutions Selected as Innovative Respiratory Device Leader to Join the NHS Innovation Accelerator Programme

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

LONDON, November 23, 2017 /PRNewswire/ —

PMD Solutions, an industry leading medical technology company based in Cork Ireland, today announced its successful enrolment in the NHS Innovation Accelerator (NIA) Programme as part of the NIA’s official kick-off launch event which took place in London this week. 

Now entering its third year, the NIA is an NHS England initiative delivered in partnership with England’s 15 Academic Health Science Networks (AHSNs) and focused exclusively on identifying and partnering with only the top leading healthcare pioneers in the market. Since its launch in July 2015, the NIA has supported the uptake and spread of 25 high-impact, evidence-based innovations across 799 NHS organisations. This recruitment process follows an international call and robust selection process, including review by a collegiate of over 100 assessors and the National Institute for Health and Care Excellence (NICE).

“We are delighted to announce our participation in the NIA Programme as this alliance represents the culmination of a lot of hard work and dedication in developing our core product RespiraSenseTM, the world’s only continuous, motion-tolerant, respiratory rate (RR) monitor,” said Myles Murray, PMD Solutions CEO. “A key focus for PMD in 2017 has been on developing our partnership channels within the NHS and building thorough educational awareness around the importance of continuous RR monitoring. Respiratory rate is the earliest indicator of patient deterioration, yet it is the most poorly measured. RespiraSenseTM has demonstrated that it can detect deterioration up to 12 hours earlier than the standard of care so we now look forward with great anticipation to delivering the very best in RR innovation across the 799 NHS organisations in the UK.”

Since 2016, PMD Solutions has been working with a network of thought leaders in the fields of early warning scoring, vital signs, and improvement in hospital systems. In 2017 PMD announced research partnerships with European Centres of Excellence in Denmark and Wales and together they continue to demonstrate the value of respiratory rate and the clinical and economic impact it has on patient care. Simon Stevens, NHS England Chief Executive said: “Modern medicine is on the cusp of a huge shift in how care is delivered, and practical innovations like these shows how NHS patients will now directly benefit. More tests and patient monitoring will be done at home or on the move, without the need to pitch up to a doctor’s appointment or hospital outpatients.”

“Since it started the NHS Innovation Accelerator has continued

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *